Clinical trial registry record

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 7, 2016.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00859898
Last registry update
July 7, 2016
Status
Completed
Phase
Phase 3
Enrollment
1093
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
INTERVENTIONAL
Evidence population
Human clinical study registration
Participants
1093
Population
Not reported
Duration
Not reported
Intervention
Dapagliflozin; Metformin XR; dapagliflozin matching Placebo; metformin HCl Modified Release matching Placebo
Comparator
Not reported
Outcomes measured
Not reported
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. It cannot show whether an intervention worked or was safe.

Safety and approvalNot reported Not reported

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Metformin · 100%Title contains controlled term: metformin. Source terminology contains: metformin. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

metformin
Read the original source →